This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We would like to thank Drs. Wisniewski and Fossati for their insightful comments on our recent article1 examining blood biomarkers associated with traumatic brain injury (TBI) and cognitive impairment (CI) in CNS-enriched exosomes. We agree that our findings of differences between the TBI and CI groups do not seem to be solely due to TBI and are most likely explained by TBI-associated CI. Indeed, our results suggest that phosphorylated tau, neurofilament light, tumor necrosis factor alpha, interleukin 6, and glial fibrillary acidic protein could differentiate non–TBI-CI from TBI-CI. Drs. Wisniewski and Fossati astutely pointed out differences between 2 different biomarker articles published by our group. These studies used different assays analyzed in separate laboratories, and study participants were different, although overlapping. However, due to the small sample size, we cannot discount the possibility of type II error in our findings with regard to Aβ42. Nonetheless, our results—along with several other imaging and biomarker studies—suggest that TBI-CI is likely to differ from classic Alzheimer disease biomarkers. We appreciate the ability to clarify the results of our article. This research is an important step to disentangling the neuropathologic underpinnings of CI after TBI, and we are excited about the inroads being made into this rapidly evolving field.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2021 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
